Dr. Zeidan on Subsequent MDS in Prostate Cancer Patients After Radiotherapy
Amer Zeidan, MBBS, MHS, assistant professor of Medicine, Hematology, Yale Cancer Center, discusses a population-based study of subsequent myelodysplastic syndromes (MDS) in prostate cancer patients after radiotherapy.
Amer Zeidan, MBBS, MHS, assistant professor of Medicine, Hematology, Yale Cancer Center, discusses a population-based study of subsequent myelodysplastic syndromes (MDS) in prostate cancer patients after radiotherapy.
Zeidan says this analysis looked at nearly 32,000 patients aged 69-99 at diagnosis who underwent surgery. The analysis compared patients who then underwent radiotherapy to those who did not. The study showed that patients who underwent radiotherapy had a slight risk of developing therapy-related MDS and acute myeloid leukemia, Zeidan says.
Therefore, physicians need to have discussions with their patients before continuing to radiotherapy.
<<<
